×

Stocks Quest Diagnostics Inc

  • Stocks pushed higher Wednesday, led by techs and banks as optimism about the economic recovery gained strength and worries about the Goldman Sach charges subsided.

  • U.S. stock index futures struggled to find direction ahead of the open Wednesday as investors braced for the next batch of corporate earnings.

  • Following are moves you might have missed. Find out why shares of Quest Diagnostics and Value Line popped while Palm dropped.

  • What follows is a look at stocks in the S&P 500 displaying unusual volume in today's trading session.

  • Following are the day’s biggest winners and losers. Find out why shares of Intel and Live Nation popped while SunTrust and Quest Diagnostics dropped.

  • Winterizing Your Portfolio - A CNBC Special Report

    Stocks advanced Monday, rebounding off of their worst week since last March, as worries about Bernanke's confirmation subsided and investors scooped up bargains. Techs advanced ahead of earnings from Apple and Texas Instruments after the bell.

  • Winterizing Your Portfolio - A CNBC Special Report

    Stocks advanced Monday, rebounding off of their worst week since last March, as worries about Bernanke's confirmation subsided and investors scooped up bargains. Techs advanced ahead of earnings from Apple and Texas Instruments after the bell.

  • What follows is a look at stocks in the S&P 500 displaying unusual volume in today's trading session.

  • Winterizing Your Portfolio - A CNBC Special Report

    Stocks advanced Monday, rebounding off of their worst week since last March, as worries about Bernanke's confirmation subsided and investors scooped up bargains. Techs advanced ahead of earnings from Apple and Texas Instruments after the bell.

  • Winterizing Your Portfolio - A CNBC Special Report

    U.S. stock index futures pointed to a strong rebound Monday after Wall Street recorded its biggest losses since the end of October on Friday.

  • earnings_central_badge.jpg

    What follows is a roundup of corporate earnings reports for Monday, Jan.  25.

  • doctor

    It appears that Washington is about to enact sweeping legislation that will be the greatest shift in public policy in decades. Yes, we can bemoan the lack of a completely private enterprise driven system but the reality is Big Brother is here and he's not going away. Without a doubt there will be implications for investors that need to be considered; and it's not all bad news from an investment perspective.

  • MM_promo_Cramerica_Challenge_530x50.jpg

    The Lightning Round is extended in this CNBC.com exclusive feature.

  • Considering investors stepped into this market and bid shares higher even with unemployment at a 26-year high, is it safe to assume the bulls are back?

  • The Lightning Round is extended in this CNBC.com exclusive feature.

  • Pharma Stocks

    Critics have been saying for years that big pharma's been pi..., er, throwing away money on relatively unproductive research and development of new drugs. But a new study shows urine could eventually provide a new revenue stream.

  • Companies that provide laboratory services are down late in the day on talk that the the new Senate Finance Committee bill on healthcare will contain a co-pay for labs that will save some $20 billion over 10 years, which may put pressure on profits of those companies.

  • Washington has doubly blessed this motor maker, Cramer says.

  • This sector offers long-term growth, even in a slowdown. Even oil can’t promise that.

  • Plus, the Mad Money host reacts to the Justice Department's probe into telecom.